The JAK1/JAK3 inhibitor tofacitinib abrogates IL-4 signaling and the differentiation of Th2 cells (45); moreover, tofacitinib is an effective and well-tolerated therapy option for people with refractory vitiligo, according to numerous research (46–49). Here, IL4 is linked to vitiligo.